Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200414 | 1.00 | CPT1A (1.00) | CPT1ATSHR | |
| SCHEMBL13969425 | 1.00 | CPT1A (1.00) | CPT1ATSHR | |
| SCHEMBL13852342 | 1.00 | CPT1A (1.00) | CPT1ATSHR | |
| SCHEMBL1743933 | 0.85 | CPT1A (0.74) | CPT1ATSHR | |
| SCHEMBL13332202 | 0.85 | CPT1A (0.74) | CPT1ATSHR | |
| SCHEMBL4202184 | 0.76 | CPT1A (0.60) | CPT1A | |
| SCHEMBL4204181 | 0.76 | CPT1A (0.60) | CPT1A | |
| SCHEMBL13946478 | 0.76 | CPT1A (0.60) | CPT1A | |
| SCHEMBL4209051 | 0.76 | CPT1A (0.60) | CPT1A | |
| SCHEMBL13946474 | 0.76 | CPT1A (0.60) | CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005435-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same | FAS SECURED CREDITORS HOLDCO, LLC | 2009-01-01 | — | — | US | disclosed |
| US-7459481-B2 | Stimulation of CPT-1 as a means to reduce weight | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE LICENSING AND TECHNOLOGY DEVELOPMENT (US) | 2008-12-02 | — | — | US | disclosed |
| US-20070087037-A1 | STIMULATION OF CPT-1 AS A MEANS TO REDUCE WEIGHT | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE LICENSING AND TECHNOLOGY DEVELOPMENT (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1758577-A2 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | Fasgen, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005117590-A2 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FASGEN, LLC (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087037-A1 | STIMULATION OF CPT-1 AS A MEANS TO REDUCE WEIGHT | CPT1B, CPT1A, CPT2 | CPT1A 2/4885TSHR 2678/4885 |
| US-20090005435-A1 | Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same | C1R, CNR1, CYP3A5 | CPT1A 365/4885TSHR 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.